EMA Authorised: Nexpovio (selinexor) — Stemline Therapeutics B.V.

View source ↗

Summary

EU authorization of Nexpovio (selinexor) for multiple myeloma, with Stemline Therapeutics B.V. as MAH, decision dated 14 August 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Nexpovio (Selinexor)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Stemline Therapeutics B.V.. Decision date: 14/08/2023